Nektar Therapeutics (Nektar) is a clinical stage drug company. It focuses on the discovery and development of novel medicines to address the unmet medical needs of patients. The company’s pipeline products comprise novel investigational medicines for treating cancer, auto-immune diseases and chronic pain. It uses a proprietary chemistry platform to discover and develop new drug candidates. Nektar has an advanced technology platform that includes novel advanced polymer technologies, which can be customized in specific ways with the objective of enhancing and improving the profiles of a broad range of molecules.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D efforts focus on the development of novel drugs and technologies related to therapy areas such as oncology, immunology and virology. -Major pipeline products include Bempegaldesleukin, NKTR-358, NKTR-288 and NKTR-255. Its lead research program is focused on developing a tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist antibody. TNFR2 signaling drives immunoregulatory function, which provides a direct protective effect for tissue cells. -Major technologies include advanced polymer conjugate technology platforms. -In FY2022, the company spent US$218.3 million on its R&D, which decreased 54.5% compared to that in the previous year. -The company has more than 300 patents in the US and 1,500 patents worldwide.